AC
AVDL

Aristides Capital’s Avadel Pharmaceuticals AVDL Stock Holding History

Aristides Capital’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-71,520
Closed -$568K – 104
2020
Q1 		$568K Hold
71,520
– – 0.41% 49
2019
Q4 		$540K Buy
+71,520
New +$378K 0.42% 103

Other funds holding AVDL

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Aristides Capital's AVDL Position: Q2 2020 in Review

Aristides Capital sold out of Avadel Pharmaceuticals (AVDL) in Q2 2020, closing a stake of 71,520 shares — an estimated $568K sold.

Aristides Capital first reported a position in AVDL in Q4 2019 and held it in 2 quarters. The position peaked at $568K in Q1 2020. 74 funds tracked by Wall St. Rank hold AVDL as of Q2 2020.

  • Aristides Capital reported no remaining Avadel Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Aristides Capital sold 71,520 Avadel Pharmaceuticals shares in Q2 2020, an estimated $568K.
  • Aristides Capital first reported a position in Avadel Pharmaceuticals in Q4 2019 and held it in 2 quarters.
  • Aristides Capital's Avadel Pharmaceuticals position peaked at $568K in Q1 2020.
  • 74 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2020.

Based on Aristides Capital's 13F filing for Q2 2020, filed 14 Aug 2020.